BriaCell Outlines New High Responding Patient Group ‘Biomarker’ Based on Cancer Grade
January 09 2020 - 05:30AM
BriaCell Therapeutics Corp. ("BriaCell" or the "Company")
(TSX-V:BCT) (OTCQB:BCTXD), a clinical-stage biotechnology
company specializing in targeted immunotherapy for advanced breast
cancer, is pleased to announce it has identified a new group of
patients with high levels of clinical benefit in response to its
novel immunotherapy, and its combinations.
Breast cancer is subdivided into 3 categories
based on its appearance under the microscope: Grade 1 (well
differentiated), Grade II (moderately differentiated) and Grade III
(poorly differentiated). The Bria-IMT™ cell line was derived from a
Grade II tumor biopsy. Upon reanalysis of our clinical data, we
learned of correlative patterns of tumor response in Grade I/II
breast cancer patient populations. In our view, this seems logical
because Bria-IMT™ is derived from a Grade II (moderately
differentiated) breast cancer tumor. Importantly, approximately 40%
of recurrent breast cancers are Grade I/II.
Monotherapy: The clinical
benefit rate in our monotherapy studies for Grade I/II patients
with immune responses was 5/7 (71%) despite the fact that these
patients were very heavily pre-treated with a median of 7 prior
regimens (such as chemotherapy).
Combination study of Bria-IMT™ with
KEYTRUDA®: All 3 patients with Grade I/II tumors had
clinical benefit (100%). All of these patients had been very
heavily pre-treated with 14-15 prior regimens.
Further analysis of our patients with Grade I/II
tumors shows that patients with greatest tumor reductions within
the Grade I/II subset also had double HLA matches with Bria-IMT™ in
both monotherapy and combination study groups. Based on our new
findings, we believe we are able to identify a sizeable patient
population who will derive significant clinical benefit from
treatment with Bria-IMT™, adding further biomarker capability
incremental to our HLA-matching hypothesis.
“We believe that we have identified an important
and sizeable subgroup of patients who will benefit from our novel
immunotherapy treatments. We plan to further validate these
findings in subsequent patients, strengthening yet another
responder biomarker technique," stated Dr. Williams, BriaCell’s
President and CEO.
About
BriaCell
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and safe approaches for
the management of cancer.
BriaCell is conducting a Phase I/IIa clinical
trial of Bria-IMT™, BriaCell’s lead candidate, in a Combination
Study with immune checkpoint inhibitors such as the Incyte drugs
INCMGA00012 (an anti-PD-1 antibody similar to pembrolizumab
[KEYTRUDA®; manufactured by Merck & Co., Inc. (NYSE: MRK)]) and
epacadostat, an orally bioavailable small-molecule inhibitor of
indoleamine 2,3-dioxygenase 1 (IDO1). The combination study is
listed in ClinicalTrials.gov as NCT03328026.
BriaCell currently has a non-exclusive clinical
trial collaboration with Incyte Corporation to evaluate the effects
of combinations of novel clinical candidates. Under the agreement,
Incyte and BriaCell will be evaluating novel combinations of
compounds from Incyte’s development portfolio with BriaCell’s drug
candidates in advanced breast cancer patients.
BriaCell is also developing Bria-OTS™, an
off-the-shelf personalized immunotherapy, for advanced breast
cancer. Bria-OTS™ immunotherapy treatments are personalized to
match the patient without the need for personalized manufacturing.
Bria-OTS™, which is expected to cover over 99 percent of the
patient population, is designed to produce a potent and selective
immune response against the cancer of each patient while
eliminating the time, expense and complex manufacturing logistics
associated with other personalized immunotherapies.
For additional information on BriaCell, please
visit: https://briacell.com/.
Cautionary Note Regarding Forward-Looking
Information
Except for the statements of historical fact,
this news release contains "forward-looking information" within the
meaning of the applicable Canadian securities legislation which
involves known and unknown risks relevant to the Company in
particular and to the biotechnology and pharmaceutical industries
in general, uncertainties and other factors that may cause actual
events to differ materially from current expectation. These risks
are more fully described in the Company's public filings available
at www.sedar.com.
Readers are cautioned not to place undue
reliance on these forward-looking statements, which speak only as
of the date of this press release. The Company disclaims any
intention or obligation, except to the extent required by law, to
update or revise any forward-looking statements, whether as a
result of new information, future events or otherwise.
Neither TSX Venture Exchange nor its Regulation
Services Provider (as that term is defined in the policies of the
TSX Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Contact Information
For further information, please
contact:BriaCell Therapeutics Corp.:Farrah
DeanManager, Corporate DevelopmentEmail: farrah@BriaCell.com Phone:
1-888-485-6340
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Feb 2024 to Mar 2024
BriaCell Therapeutics (TSXV:BCT)
Historical Stock Chart
From Mar 2023 to Mar 2024